Propanc Biopharma, Inc. (PPCB) stock
PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$1.94+0.02 (+1.09%)
Close on Nov 13, 2026Market cap $12.29MP/E –Yield –
Propanc Biopharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$17.62. The highest annual figure on record is -$17.62 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$17.62 | – |
| FY2025 | Jun 30, 2025 | -$371.22 | – |
| FY2024 | Jun 30, 2024 | -$1420.53 | – |
| FY2023 | Jun 30, 2023 | -$107969.40 | – |
| FY2022 | Jun 30, 2022 | -$2952963.09 | – |
| FY2021 | Jun 30, 2021 | -$47986.40 | – |
| FY2020 | Jun 30, 2020 | -$11543728.35 | – |
| FY2019 | Jun 30, 2019 | -$658013.51 | – |
| FY2018 | Jun 30, 2018 | -$10721961.25 | – |
| FY2017 | Jun 30, 2017 | -$67180960.00 | – |
| FY2016 | Jun 30, 2016 | -$144858945.00 | – |
| FY2015 | Jun 30, 2015 | -$149957500.00 | – |
| FY2014 | Jun 30, 2014 | -$74978750.00 | – |
| FY2013 | Jun 30, 2013 | -$149957500.00 | – |
| FY2012 | Jun 30, 2012 | -$1199660000.00 | – |
| FY2011 | Jun 30, 2011 | -$224936250.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$12.22 | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$0.28 | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$0.30 | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$98.08 | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$12.50 | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$32.23 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$35.97 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$545.79 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$1559.55 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$2399.32 | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$25192.86 | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$31790.99 | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$127763.79 | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$632.98 | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$1199.66 | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$1199.66 | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$7197.96 | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$26992.35 | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$42587.93 | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$20919071.25 | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$75025536.74 | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$84576.03 | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$53384.87 | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$2479097.39 | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$599830.00 | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$1799490.00 | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$5998300.00 | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$10796940.00 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$11396770.00 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$33890395.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?